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N-acetylcysteine (NAC) is known in a variety of branches of medicine. This paper addresses
in detail the action of NAC as it is emerging from research and clinical trials over the past
decade in cardiology, giving rise to new concepts. The result is a process resembling creation
of a mosaic from individual pieces. Also, the role of NAC in acute cardiology, during acute
reperfusion in particular, is defined. (J Am Coll Cardiol 2002;39:1422–8) © 2002 by the
American College of Cardiology Foundation
N-acetylcysteine (NAC) is known in a variety of branches of
medicine. In cardiology, it has been increasingly used over
the past decade, with its main potential being the minimi-
zation of the impact of reperfusion injury on the treatment
of acute myocardial infarction. Still, the spectrum of its
effects is much broader: it has an effect on oxygen radicals;
it may protect, via sulfhydryl groups, the key regions of the
cellular membrane; it exerts an effect on endothelial function
and a complex of adhesive processes and, as a secondary
effect, also processes in the extravascular compartment.
Additionally, it possesses a variety of other actions to be
discussed. Moreover, it is related to the whole cardiovascular
system.
OXIDATIVE STRESS
Problem description. Throughout its life, the cell is ex-
posed to the action of molecular oxygen in a host of redox
processes. Oxygen radicals are produced even under resting
conditions. It is estimated that mitochondria turn about 2%
of the total amount of oxygen processed into superoxide
ions and not into the normal end product, which is water
(1). The superoxide ion is subsequently converted—with the
action of metalloproteins, most often lactoferrin containing
iron from neutrophil granules (Fenton’s reaction)—via hy-
drogen peroxide as an intermediary product into a hydroxyl
radical. Alternatively, by direct reaction with hydrogen
peroxide, again giving rise to a hydroxyl radical and oxygen
singlet (Haber-Weiss reaction). Oxygen radicals are respon-
sible for a variety of other processes and so-called oxidative
stress in particular, with the latter referring to a complex of
various abnormal processes affecting the isolated cell, the
tissue, or the whole body (2–4). The importance of these
processes is particularly evident when the cell is unable to
defend itself against the radicals, such as when it is exposed
to excessively high concentrations of free oxygen radicals of
exogenous origin in a phase when it is injured and loses
defensive mechanisms or when it excessively produces free
radicals. Oxidative stress may result in a temporary or
permanent change in the properties of proteins and, possi-
bly, in a change in nucleic acids (5–7). The process of aging
is generally believed to be simply a consequence of long-
term exposure to oxygen radicals (8–10).
Reperfusion as a deleterious process. Reperfusion is
based on the reintroduction of fully oxygenated blood into
the targeted areas of myocardium previously modified by
ischemia. This is associated with exacerbation of various
stages of cellular injury as assessed by morphological, phys-
iological and biochemical criteria. The typical sequels of
reperfusion injury are release of intracellular enzymes, al-
tered calcium ion homeostasis with their intracellular influx,
and sarcolemmal phospholipid breakdown terminated by
cell membrane disruption. This ultimate stage is called
lethal reperfusion injury and is synonymous with cell and
tissue necrosis as a measurable parameter. Under normal
conditions, existing cardiomyocyte homeostasis often un-
dergoes two combined processes: functional changes and
structural changes. Functional changes involve electrical
instability with a broad range of ventricular arrhythmias and
depressed ventricular contractility (stunning). Structural al-
terations consist of microvascular lesions (slow-flow, no-
reflow phenomenon), hemorrhagic intramyocardial foci and
non-apoptotic cellular death in the end stage. Myocardial
reperfusion injury involves the reperfusion-induced conver-
sion of reversible injured myocardial and endothelial cells, as
well as interstitial tissue, into irreversibly altered cells. It
implies that cells in potentially viable conditions just before
reperfusion underwent lethal injury during the perireperfu-
sion period.
Elementary findings. In cardiology, the target cell—the
cardiomyocyte—possesses both structural and functional
properties as volume regulation, conduction and contrac-
tion. Some 10 years ago, the concept of oxidative stress
was fairly mysterious. Currently, there is a trend toward a
renaissance of previously recognized findings. In 1935,
Tennant and Wiggers (11) described ventricular fibrillation
after release of coronary artery ligation. The accelerated
idioventricular rhythm was reported by Goldberg et al. (12)
after the introduction of reperfusion therapy into clinical
practice. In 1975, Heyndrickx et al. (13) gave an account of
post-ischemic contractile myocardial dysfunction after
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reperfusion. Since 1982, when Braunwald and Kloner (14)
renamed the condition as “stunned myocardium,” it has
become a generally recognized phenomenon after all types
of acute reperfusion. This refers to the functional conse-
quences of reperfusion on the myocardium. The primary
causes may be processes leading to sulfhydryl group (-SH)
oxidation (15). Oxidative stress occurs after reperfusion
therapy for acute myocardial infarction (MI), irrespective of
the method of reperfusion (i.e., medical or mechanical
therapy) (16,17). Recently, a rise in oxygen radicals during
treatment of acute MI using percutaneous transluminal
coronary angioplasty was reported (18).
Current concepts. Essentially, these processes involve an
action of free oxygen radicals on unsaturated fatty acyl
chains in cell phospholipids and their peroxidation (the
process affects both the cellular membrane and lysosomes)
(19–21). This results in damage of lysophosphatidyl acyl-
transferase, i.e., an -SH sensitive enzyme with a subsequent
impact on further changes in the glutathione system (re-
sponsible for redox elimination of oxygen radicals) (22). If
prolonged, oxidative stress may result in structural alter-
ations. Of the three possibilities—hemorrhage, microvas-
cular damage and cell necrosis—the latter is, in the case of
reperfusion, called lethal reperfusion injury. This occurs
mostly in situations when the myocyte is significantly
damaged by previous prolonged ischemia. A piece of evi-
dence indicating these processes are very topical, especially
today when the mainstay of therapy is one of the techniques
of reperfusion, is supplied by principles of cellular defense
that have been identified. Today, the elementary features of
gene expression have been defined for so-called ARE
(antioxidant reactive elements), after an ischemia-
reperfusion experiment lasting no more than dozens of
minutes (23). Theoretically, and philosophically as well, the
first episode of oxidative stress is birth, when the lungs of
the neonate are filled with oxygen. Nature would certainly
not fail to include this event in the evolutionary process. In
1989, the potential for pharmacological protection of the
myocardium against reperfusion injury by thiol-containing
agents (i.e., those containing -SH groups) at the time of
release of the coronary artery ligature (i.e., in the reperfusion
phase of the experiment) was first described, which was,
until then, regarded as non-feasible (24).
In addition to this common situation (in cardiology),
oxidative disorders are associated with a number of chronic
conditions. Chronic heart failure (HF) is a case in point, as
the condition has been clearly associated with -SH group
depletion and an increased incidence of apoptosis. Like -SH
group oxidation in acute conditions (ischemic-reperfusion
processes), apoptosis in chronic conditions has been ex-
plained by DNA oxidation (the implication being it is of
importance with chronic HF of any etiology) (15). Unde-
sirable oxidative damage to myocardial and vascular cells in
general occurs also with nitrate tolerance (this is also
explained by -SH group depletion, increased production of
oxygen radicals with an effect on cyclic guanosine mono-
phosphate and loss of cell relaxation). Diastolic HF is
possibly caused by similar processes.
Free oxygen radicals and their role. The free oxygen
radical hypothesis seems to be the most widely recognized
aspect of reperfusion injury because of both the direct and
indirect evidence supporting it. In fact, free oxygen radicals
are involved in various pathways in the form of calcium
overload of cardiomyocytes and the spectrum of sarcolem-
mal phospholipid changes that are present in the initial
phase of membrane injury. Measurable changes include hy-
droxyl radical detection and lipid oxidation (lipid endoperox-
ides, lipid hydroperoxides and conjugated dienes formation).
The transient role of superoxides, with their ultrashort half-life,
is also well defined. These processes are also enhanced by
conversion of xanthine dehydrogenase into xanthine oxygen-
ase. On the other hand, many substances such as antioxidants
and/or free-radical scavengers have been shown to minimize
reperfusion injury and indirectly support the key role played by
oxygen radicals in reperfusion injury.
Of special importance are processes involved in the so-called
endogenous antiradical defense. These include, in particular,
binding to albumin and hemoglobin, reactions with various
lipids with no essential function, and reaction with the urate
system. Additionally, there is evidence on external enhance-
ment of these processes, for example, superoxide dismutase
(targeted on the superoxide anion), catalase (inactivating pri-
marily hydrogen peroxide), allopurinol and ascorbic acid. The
role of alpha-tocopherol is currently being re-examined. Com-
pared with free radicals, lipid peroxides are relatively more
stable and less sensitive to the effect of natural defense; thus,
they can be used as a measurable index of reperfusion injury
(method using phenyl-tert-butylnitron).
Today, it seems that the theory of oxidative stress ceases
to be mere theory; and accumulating evidence in the fields
of molecular cardiology, biochemistry and gene expression/
re-expression may result in new therapeutic approaches.
SULFHYDRYLS, MEMBRANE INJURY,
REGIONAL REPERFUSION AND
N-ACETYLCYSTEINE (NAC) OVER THE PAST 10 YEARS
Experimental model. We have been studying intensively
the issue of regional reperfusion in acute MI since 1984 (i.e.,
Abbreviations and Acronyms
GISSI  Gruppo Italiano per lo Studio della
Streptochinasi nell’ Infarto Miocardico study
GUSTO  Global Utilization of Streptokinase and
T-PA for Occluded Coronary Artery trial
ISIS  International Study of Infarct Survival
ISLAND  Infarct Size Limitation: Acute
N-acetylcysteine Defense trial
MPG  mercaptopropionyl glycine
NAC  N-acetylcysteine
-SH  sulfhydryl groups
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at the time when thrombolytic therapy was relatively well
established). The experience gained led to an effort to
minimize the extent of myocardial injury. In 1990, we
performed an experimental study in dogs with 2 h of
ischemia and 2 h reperfusion: NAC was administered at a
total dose of 100 mg/kg b.w., so most of the dose coincided
with the reperfusion phase of the experiment. This resulted
in reduction of structural injury (smaller extent of necrosis)
compared with a control group of animals. Similarly, a
significant reduction in the incidence of ventricular arrhyth-
mias as a functional consequence was seen in the reperfusion
phase in the treated group (25). Because of the surprising
results, the study was repeated, and the results were con-
firmed (26). At that time, NAC had been selected on the
basis of a thorough study of the substance showing a unique
spectrum of effects; and, most importantly, it was readily
available.
Biochemical view. A chemically similar substance, amino-
ethanethiol, was first used in 1960. At that time, this
substance was intended to confer protection against the
effects of radiation (27). Seen from today’s perspective,
aminoethanethiol is referred to as cysteamine, and
radiation-induced alterations at the cellular level are not
dissimilar to the ischemia-reperfusion insult. Another prop-
erty of cysteamine that seemed to be an advantage was its
ability to act at a low pH, i.e., under acidotic conditions,
which exist as a rule in the ischemic phase of experiments.
Needless to say, the element most affected by the ischemic
and reperfusion burden is the cellular membrane. An
accompanying process is a decrease in thiols and -SH
(28,29). Substances containing -SH groups may confer a
protective effect. Dimethylthiolurea was such a successful
candidate, improving left ventricular (LV) contractility,
most likely via hydroxyl radical elimination (30). A most
important finding was that -SH-containing substances may
be effective even when administered at the time of reperfu-
sion; initially, it was believed that protective agents should
be administered exclusively in the ischemic phase of exper-
iments. Mercaptopropionyl glycine (MPG) works in an
exactly identical manner as when administered before cor-
onary artery occlusion (24). The effects of MPG were
known from an earlier pharmacological study (31). Mercap-
topropionyl glycine is a direct free-radical scavenger. Sulf-
hydryl groups are oxidizable structures, thus explaining the
elimination of free oxygen radicals. The importance of the
cysteine-cystine redox system is well known in terms of its
biochemistry. Moreover, -SH groups can easily bind with
free -SH groups of structural and functional membrane
proteins and prevent—at least temporarily—their damage.
It is by this particular mechanism that reactive enzyme
groups are protected reversibly against the effects of perox-
ides and, possibly, other radicals. This is the assumed result
of mixed disulfides and the main role of disulfide bonds.
Cysteine is clearly a metabolite of NAC in vivo (32). There
is also an important relationship between cysteine and/or
NAC and glutathione: cysteine can be clearly regarded as a
glutathione precursor (33,34). Glutathione, and/or the ratio
between its reduced and oxidized phases, is a directly
measurable marker whose dynamics in an ischemic-
reperfusion insult are related to cardiac function (35,36).
Glutathione peroxidase is an important enzyme in the
degradation cascade of reactive free oxygen radicals. In this
respect, NAC may help replenish the depleted glutathione
stores (37). Early pharmacologic studies reported an effect
of NAC in a model of ischemia-reperfusion (38).
N-acetylcysteine is most likely also related to the modula-
tion of damaged endothelium. The endothelium, in the
phase of cellular swelling, no-reflow phenomenon and,
possibly, the more substantial changes, cannot produce the
endothelium-derived relaxing factor (nitric oxide). Hypo-
thetically, the role can be taken over by the positive action of
the -SH groups of NAC and routinely administered nitro-
glycerin replacing the missing nitric oxide. This action,
however, does not involve direct elimination of free oxygen
radicals. We will not address the issue of nitrate tolerance.
Still, in the context of oxygen radical generation and
no-reflow phenomenon, mention should be made of the
interaction of neutrophils, endothelia and intercellular ad-
hesion molecule-1. The oxidase system of neutrophils and
free oxygen radicals may substantially affect the MAC-1
neutrophil receptors (CD11b/CD18), thus modulating
thrombocyte behavior, vascular permeability and release of
agents from mast cells and, by this mechanism, affect the
vascular and extravascular compartment interface (39,40).
At least a decrease in circulating polymorphonuclear neu-
trophils and hydrogen peroxide levels after NAC adminis-
tration has been documented (41). In general, cysteine
derivatives show a certain anticoagulation activity that is
beneficial in coronary thrombosis. A report was published as
early as 1952 describing a decrease in prothrombin activity
(prothrombin time prolongation) several hours after cyst-
amine administration (42). Finally, NAC may also be an
angiotensin-converting enzyme inhibitor: NAC signifi-
cantly reduces (by 50%) angiotensin II levels in humans and
angiotensin-convertase activity by 31% in the plasma of rats
(43). Basal NAC pharmacokinetics in man has been inves-
tigated in detail (44).
Pharmacology of NAC. N-acetylcysteine is a well-
documented substance in medicine. Its defined volume of
distribution is 0.33 l/kg, its renal clearance is 0.21 l/h per kg,
and its elimination half-life is 2.27 h (44). Originally, NAC
has been used to liquefy mucus in bronchi; NAC is also the
antidote for paracetamol poisoning. It should also be men-
tioned that cysteine derivatives have been intensively inves-
tigated in military medicine because of their protective
effects against radiation and that NAC has been investigated
as a modulator of radiographic contrast agent–induced
nephrotoxicity (45–47).
From the point of cardiology, it is important that NAC is
readily hydrolyzed to cysteine and can arise from essential
methionine (an amino acid containing an atom of sulfur).
Cysteine is a precursor of glutathione. By itself, cysteine has
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no significant hemodynamic effects; but, when combined
with nitrates (the indication being either enhancement of
the nitrate mechanism or elimination of nitrate tolerance
through -SH donation), it may cause a decrease in blood
pressure and, possibly, headache via intracranial blood bed
dilation. These findings were made, for example, in a study
addressing the management of unstable angina pectoris and
comparing the effects of intravenous nitroglycerin versus a
combination of intravenous nitroglycerin and NAC (48).
However, the most important finding of this study was a
reduction in the incidence of MI. Similarly, another ran-
domized study involving the same category of patients
compared transdermal nitroglycerin with nitroglycerine/
NAC: although all the outcomes of unstable angina pectoris
were reduced significantly by combination therapy, a rela-
tively high incidence of induced headache was demonstrated
(49). Induced vasodilation can be used even in the treatment
of lung edema or congestive HF. A randomized study
confirmed an equal effect of conventional therapy for acute
cardiogenic pulmonary edema with furosemide and mor-
phine versus the tested combination of nitroglycerine and
NAC (50). Another randomized study conducted in pa-
tients with chronic HF demonstrated that a combination of
isosorbide dinitrate and NAC results in a more significant
effect on preload than isosorbide dinitrate alone. Moreover,
the former combination significantly reduced the plasma
levels of atrial natriuretic peptide (51). This has clear
implications for prevention of pulmonary congestion. Its
effect on platelets is yet another, by no means negligible,
action of this molecule. A significant effect of the combi-
nation of NAC and nitroglycerin on inhibiting platelet
thrombus formation has been reported, whereas the dose of
nitroglycerin, when used alone, had no effect whatsoever
(52). Intervention regarding low-density lipoprotein oxida-
tion to oppose atherogenesis seems to be another promising
line of research.
Despite this, new combinations of NAC action under
pathophysiologic conditions, particularly in ischemia-
reperfusion situations, continue to emerge. The role of
NAC in various pharmacologic and clinical interventions is
shown in Tables 1 and 2.
Clinical baseline. These unique properties of NAC, its
demonstrated role in clinical practice from other indica-
tions, and results of early experimental studies imitating
ischemia-reperfusion conditions led to clinical trials with
NAC in acute cardiology. The first clinical observation in
1991 documented normalization of LV function after a
previous infarction (53). This served as a stimulus to launch
a pilot study referred to as ISLAND (Infarct Size Limita-
tion: Acute N-acetylcysteine Defense trial) (54). This was
followed by a detailed analysis of the data obtained and
waiting for results from other centers (55–58). Clinical
studies regarding the role of NAC in modulating ischemic-
reperfusion injury in acute MI and conducted to date are
very small, yet they have yielded positive results. The first
study, published in 1995, reported data obtained from 29
consecutive patients: of this number, only 27 were eligible.
A total of 20 patients were assigned to combination therapy,
including streptokinase, NAC and nitroglycerin. The re-
maining seven patients were treated without NAC (56).
The ISLAND study, published in 1996, was already a
randomized, angiography- and echocardiography-
controlled study. Of the total 57 consecutive patients, 45
were randomized: 21 patients were treated with streptoki-
nase and 19 with a combination of streptokinase and NAC.
Five patients were ineligible for analysis. Angiography
divided the whole series of patients into 14 patients with
reperfusion induced by combination therapy, 15 patients
with reperfusion induced by streptokinase alone and 11
patients with failed reperfusion. The main analysis focused
on the 14 patients receiving combination therapy with
angiography-documented reperfusion; this group was com-
pared with the other groups. The first group differed clearly
from other groups by a reduction in infarct size and
improved LV function as shown by electrocardiogram.
Similarly, the whole group of 19 patients receiving combi-
Table 1. Major Clinical Roles for NAC
Historically Relation to cysteamine—a radioprotective agent
(military use)
Noncardiac uses Bronchosecretolytic
Antidote in paracetamol poisoning
Antinephrotoxic effect (prevention of
radiographic contrast agent-induced renal
function alteration)
General uses in
cardiology
Vasodilation and induced left ventricular effect
Donation of -SH groups
Nitrate enhancement
Vascular/platelet effect
Application: antianginal effect
heart-failure modulation
Other effects Mainly in research: stabilization of
atherosclerotic process
Modulation of cell death protection
NAC  N-acetylcysteine; -SH  sulfhydryl groups.
Table 2. Postulated Roles for NAC in Acute Cardiology
Target: Ischemic-Reperfusion Effect
Factors involved: (a) direct protection against effects of FOR
(aa) redox mechanism cysteine-cystine
(ab) relation to glutathione
(b) indirect protection against FOR, formation of mixed
disulfides with -SH groups of membrane
peptide/enzymes
(c) effect on modulating processes and factors
(ca) effect on platelet function
(cb) action under low-pH (ischemic) conditions
(cc) interaction with neutrophils
(cd) NAC  ACE inhibition
(ce) modulation of coagulation
(cf) effect on adhesion processes (via adhesion
molecules)
(cg) arrhythmogenesis modulation
NAC action outside the area of acute cardiology is outside the scope of this article,
which is why they are mentioned only briefly.
ACE  angiotensin-converting enzyme; FOR  free-oxygen radicals; NAC 
N-acetylcysteine; -SH  sulfhydryl groups.
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nation therapy differed, regardless of the result of coronary
angiography, from the group of 21 patients treated exclu-
sively with streptokinase (58). A summary of data is shown
in Table 3.
An important finding was that there is an electrocardio-
graphic marker indicating an additional beneficial func-
tional effect: a rudimentary R wave or R wave recovery in the
left precordial leads (55,59). For the purpose of more
accurate quantification of risk region and final infarct size,
there are methods available, such as nuclear imaging,
echocardiography and myocardial blush grading. At the
same time, basic research provided evidence of an associa-
tion between free oxygen radicals and arrhythmogenesis in
the modulation of calcium-sensitive nonselective cation
current irrespective of changes in intracellular calcium ion
levels. Most likely, there is a mechanism that modulates the
membrane channels by -SH: dithiothreitol inhibits nonse-
lective cation current activation (60). This finding in pigs is
fully consistent with our previous finding made in dogs at a
time when the role of transmembrane current and modified
channels was not yet known (25).
WAITING FOR ADDITIONAL EVIDENCE
NAC today. N-acetylcysteine has been selected for use in
ischemia-reperfusion injury more or less empirically. Today,
it seems to have a place in cardiology—particularly in acute
cardiology—as an agent specifically modulating reperfusion
injury (61). The number of papers indicating the impor-
tance of NAC in basic research, experimental and clinical
cardiology, cardiac surgery, as well as in other branches of
medicine, has been growing. A list of references from all
fields is outside the scope of this communication; however,
representative papers underlining the comprehensive nature
of the effect of NAC are included. This is logical because
this perspective clearly shows the interplay of individual
pathophysiological processes. Today, NAC is perceived as
a drug applicable in acute coronary syndromes (62).
N-acetylcysteine directly eliminates hydroxyl radicals and
increases the nitric-oxidase system-dependent coronary flow
(63). This is an advantage when using NAC as part of
cardioplegic solutions (64). Evidence is also available that
NAC acts during cardiopulmonary bypass as an oxygen
radical scavenger and also stabilizes neutrophils in relation
to their oxidative response to the bypass (65). In this
context, the interaction of effects on the intravascular and
extravascular compartment interface is also of importance.
Through its action on vascular cell adhesion molecules-1
and action of endothelium-mediated adhesiveness via nu-
clear factor-kappa B, NAC may reduce the impact of
oxidative stress (66,67). Furthermore, NAC improves
endothelium-dependent vasodilation both on peripheral
and coronary arteries (68). Not irrelevant in this context is
the finding that NAC decreases plasma homocysteine levels
(69). The reduction may be as high as 60% or more (70).
The complex of NAC effects is complemented by a series of
findings revealing that the substance reduces oxidative
lesions in target tissue, allows adequate oxygen utilization
and improves overall oxygenation, with a potential reduc-
tion in mechanical ventilation both in lung injury and in
hyperoxemic situations or during hyperbaroxia (71–73).
Finally, there is a report wherein NAC modulated the
course of severe systolic dysfunction in patients with viral
myocarditis (74).
WHAT WE KNOW AND WHAT WE WANT TO KNOW
Present status. First, a large body of evidence has been
accumulated from basic research, experimental physiology
and cardiology and also from other clinical subspecialties (a
basic review is provided in this communication).
Second, we are aware of several experimental studies not
confirming a beneficial effect of NAC; however, no study
has demonstrated deleterious effects of NAC, the number of
papers reporting a beneficial effect of NAC is incomparably
higher than those not confirming a beneficial effect, and
there is a lack of comparability in the methods used.
Third, we know that small clinical studies demonstrating
an effect of NAC have been conducted in acute and
reperfusion cardiology.
Fourth, we know that the past 10 years have not dimin-
ished—but have not boosted—the importance of NAC.
Question formulation. It is therefore logical to formulate
what we want to learn: Is NAC clearly a beneficial agent
reducing reperfusion injury in the treatment of acute MI as
practiced today? To be able to answer this question, a large
randomized multicentric study of the scope of GISSI, ISIS
or GUSTO would be required.
Table 3. Current Independent Pilot Clinical Studies With NAC in Acute Myocardial Infarction
Study Result
Arstall et al. (53) Decreased level of oxidative stress
n  27 (20 with combination therapy) More rapid reperfusion
Better left ventricular preservation
ISLAND (55) Reduced infarct size
n  45 (19 with combination therapy,
14 with proven reperfusion)
Better preservation of global and regional left
ventricular function
Modification of QRS complex morphology in ECG
ECG  electrocardiogram; ISLAND  Infarct Size Limitation: Acute N-acetylcysteine Defense trial; NAC 
N-acetylcysteine.
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